28455257|t|Molecular insights into the inhibitory mechanism of rifamycin SV against β2-microglobulin aggregation: A molecular dynamics simulation study
28455257|a|Dialysis-related amyloidosis (DRA) is a severe condition characterized by the accumulation of amyloidogenic β2-microglobulin (β2m) protein around skeletal joints and bones. The small molecules that modulate β2m aggregation have been identified in vitro, however, the underlying inhibitory mechanism remain elusive. In the present study, molecular docking and molecular dynamics (MD) simulations were performed to elucidate the inhibitory mechanism of an antibiotic, rifamycin SV (C1) reported for its in vitro anti-aggregation activity against β2m. The molecular docking analysis highlight that C1 display hydrophobic contacts with residues in the aggregation prone region of β2m. MD simulations reveal enhanced structural stability of β2m in the presence of C1. C1 inhibit the conformational transition of the C-terminal region of β2m from a β-sheet to random coil conformation, which is reported for the initiation of fibrillogenesis of β2m. The results of the present study provide insight into the key interactions and underlying inhibitory mechanism of a small molecule against β2m aggregation that will help in the design and development of more potent, novel inhibitors of β2m aggregation.
28455257	28	38	inhibitory	T052	C3463820
28455257	39	48	mechanism	T169	C0441712
28455257	52	64	rifamycin SV	T109,T195	C0073371
28455257	73	89	β2-microglobulin	T116,T123	C0005149
28455257	90	101	aggregation	T044	C3850147
28455257	105	134	molecular dynamics simulation	T066	C2717775
28455257	141	157	Dialysis-related	T037	C3266969
28455257	158	169	amyloidosis	T047	C0002726
28455257	171	174	DRA	T047	C0002726
28455257	235	248	amyloidogenic	T116,T123	C1456454
28455257	249	279	β2-microglobulin (β2m) protein	T116,T123	C0005149
28455257	287	295	skeletal	T082	C0521324
28455257	296	312	joints and bones	T030	C0545594
28455257	348	351	β2m	T116,T123	C0005149
28455257	352	363	aggregation	T044	C3850147
28455257	385	393	in vitro	T080	C1533691
28455257	419	429	inhibitory	T052	C3463820
28455257	430	439	mechanism	T169	C0441712
28455257	478	495	molecular docking	T063	C3494273
28455257	500	535	molecular dynamics (MD) simulations	T066	C2717775
28455257	568	578	inhibitory	T052	C3463820
28455257	579	588	mechanism	T169	C0441712
28455257	595	605	antibiotic	T195	C0003232
28455257	607	619	rifamycin SV	T109,T195	C0073371
28455257	621	623	C1	T109,T195	C0073371
28455257	642	650	in vitro	T080	C1533691
28455257	685	688	β2m	T116,T123	C0005149
28455257	694	720	molecular docking analysis	T063	C3494273
28455257	736	738	C1	T109,T195	C0073371
28455257	747	767	hydrophobic contacts	T044	C0678607
28455257	789	800	aggregation	T044	C3850147
28455257	817	820	β2m	T116,T123	C0005149
28455257	822	836	MD simulations	T066	C2717775
28455257	853	873	structural stability	T080	C2350440
28455257	877	880	β2m	T116,T123	C0005149
28455257	900	902	C1	T109,T195	C0073371
28455257	904	906	C1	T109,T195	C0073371
28455257	919	944	conformational transition	T044	C0301641
28455257	952	969	C-terminal region	T087	C1707271
28455257	973	976	β2m	T116,T123	C0005149
28455257	984	991	β-sheet	T082	C0162806
28455257	995	1006	random coil	T087	C0599218
28455257	1007	1019	conformation	T082	C0033625
28455257	1061	1076	fibrillogenesis	T044	C3544412
28455257	1080	1083	β2m	T116,T123	C0005149
28455257	1175	1185	inhibitory	T052	C3463820
28455257	1186	1195	mechanism	T169	C0441712
28455257	1224	1227	β2m	T116,T123	C0005149
28455257	1228	1239	aggregation	T044	C3850147
28455257	1307	1317	inhibitors	T120	C0243077
28455257	1321	1324	β2m	T116,T123	C0005149